$STTK News

Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update - Slideshow

What's Going On With Shattuck Labs Stock Wednesday?

Shattuck Labs: "Hold" On Phase 1  SL-325 Data And Next Stage Of Development

Shattuck Labs Commences Common Stock Offering; Terms Undisclosed

Citigroup Maintains Buy on Shattuck Labs, Raises Price Target to $18

Shattuck Labs Announces Total Expected Proceeds Of ~$59.4M From Exercised Warrants

Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update Transcript

Why Is Shattuck Labs Stock Trading Lower On Monday?

Needham Maintains Buy on Shattuck Labs, Raises Price Target to $17

HC Wainwright & Co. Reiterates Buy on Shattuck Labs, Maintains $18 Price Target

Shattuck Reports Phase 1 Data for SL-325 Antibody

Shattuck Labs To Host Investor Call And Webcast On June 8 To Present Comprehensive Phase 1 Clinical Data For SL-325 And Provide Pipeline Update

Citigroup Upgrades Shattuck Labs to Buy, Announces $7 Price Target

Shattuck Labs: Priced As If Risk Was Not A Part Of The Equation

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Wedbush Maintains Outperform on Shattuck Labs, Raises Price Target to $11

Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights

Shattuck Labs Q1 EPS $(0.13), Inline

Cantor Fitzgerald Initiates Coverage of Shattuck Labs (STTK)

Cantor Fitzgerald Initiates Coverage On Shattuck Labs with Overweight Rating